NASDAQ:UPB Upstream Bio (UPB) Stock Price, News & Analysis $2.00 -0.08 (-3.85%) Closing price 04:00 PM EasternExtended Trading$2.02 +0.02 (+0.75%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Upstream Bio Stock (NASDAQ:UPB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Upstream Bio alerts:Sign Up Key Stats Today's Range$2.00▼$2.1950-Day Range$2.08▼$5.8152-Week Range$2.00▼$33.68Volume856,120 shsAverage Volume906,898 shsMarket Capitalization$109.62 millionP/E RatioN/ADividend YieldN/APrice Target$26.67Consensus RatingHold Company Overview Upstream Bio is a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases. The company is based in Waltham, Massachusetts, and its research focuses on pathways involved in immune and inflammatory responses. Its lead product candidate, verekitug (UPB-101), is an antibody designed to block the receptor for thymic stromal lymphopoietin, a protein associated with inflammation. Upstream Bio is developing verekitug for conditions including asthma and chronic rhinosinusitis with nasal polyps. The company’s work is focused on drug development and clinical research; it does not have a marketed product portfolio.AI Generated. May Contain Errors. Read More Upstream Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreUPB MarketRank™: 3.492355992355 of 5 starsUpstream Bio scored higher than 70% of companies evaluated by MarketBeat, and ranked 513th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingUpstream Bio has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialUpstream Bio has a consensus price target of $26.67, representing about 1,233.3% upside from its current price of $2.00.Amount of Analyst CoverageUpstream Bio has only been the subject of 2 research reports in the past 90 days.Read more about Upstream Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Upstream Bio are expected to grow in the coming year, from ($2.81) to ($2.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Upstream Bio is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Upstream Bio is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUpstream Bio has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.76% of the float of Upstream Bio has been sold short.Short Interest Ratio / Days to CoverUpstream Bio has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Upstream Bio has recently decreased by 20.77%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUpstream Bio does not currently pay a dividend.Dividend GrowthUpstream Bio does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.54 News SentimentUpstream Bio has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Upstream Bio this week, compared to 2 articles on an average week.Search Interest4 people have searched for UPB on MarketBeat in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Upstream Bio insiders have not sold or bought any company stock.Percentage Held by Insiders16.46% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsUpstream Bio has minimal institutional ownership at this time.Read more about Upstream Bio's insider trading history. Receive UPB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. UPB Stock News HeadlinesHC Wainwright Increases Earnings Estimates for Upstream BioNovember 15, 2026 | americanbankingnews.comUpstream Bio (NASDAQ:UPB) Stock Gets Price Target Reduction from HC WainwrightNovember 14, 2026 | americanbankingnews.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 19 at 1:00 AM | Base Camp Trading (Ad)Upstream Bio, Inc. (UPB) - What Are Researchers Saying About This Stock?November 13, 2026 | americanbankingnews.comUpstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued ProgressNovember 10, 2026 | globenewswire.comUpstream Bio Reports Phase 2 VALIANT Trial Results Showing Verekitug Reduced Severe Asthma Exacerbations by 56% with Quarterly DosingSeptember 8, 2026 | quiverquant.comQUpstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026September 8, 2026 | globenewswire.comAnalysts Are Bullish on These NA Stocks: Upstream Bio, Inc. (UPB), Fervo Energy Company Class A (FRVO)September 2, 2026 | theglobeandmail.comSee More Headlines UPB Stock Analysis - Frequently Asked Questions How have UPB shares performed this year? Upstream Bio's stock was trading at $27.15 at the beginning of the year. Since then, UPB shares have decreased by 92.6% and is now trading at $2.00. How were Upstream Bio's earnings last quarter? Upstream Bio, Inc. (NASDAQ:UPB) issued its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.73) by $0.02. The business earned $395 thousand during the quarter, compared to analyst estimates of $549 thousand. Upstream Bio had a negative net margin of 5,712.33% and a negative trailing twelve-month return on equity of 57.09%. When did Upstream Bio IPO? Upstream Bio (UPB) raised $200 million in an initial public offering (IPO) on Friday, October 11th 2024. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair served as the underwriters for the IPO. Who are Upstream Bio's major shareholders? Top institutional shareholders of Upstream Bio include Goldman Sachs Group Inc. (2.06%), State Street Corp (1.34%), Samsara Biocapital LLC (0.55%) and Jump Financial LLC (0.37%). Insiders that own company stock include Erez Chimovits, Ai Upstream Llc and Michael Gray. View institutional ownership trends. How do I buy shares of Upstream Bio? Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/10/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 UPB's financial health is in the Red zone, according to TradeSmith. UPB has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:UPB Previous SymbolNASDAQ:UPB CIK2022626 Webupstreambio.com Phone(781) 208-2466FaxN/AEmployees75Year Founded2021Price Target and Rating Average Price Target for Upstream Bio$26.67 High Price Target$50.00 Low Price Target$9.00 Potential Upside/Downside+1,233.3%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($3.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$143.44 million Net Margins-5,712.33% Pretax Margin-5,712.33% Return on Equity-57.09% Return on Assets-54.69% Debt Debt-to-Equity RatioN/A Current Ratio20.45 Quick Ratio20.45 Sales & Book Value Annual Sales$2.87 million Price / Sales38.20 Cash FlowN/A Price / Cash FlowN/A Book Value$4.27 per share Price / Book0.47Miscellaneous Outstanding Shares54,811,000Free Float45,789,000Market Cap$109.62 million OptionableOptionable Beta1.60 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:UPB) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.